Arun Jaiswal | Genetics and Molecular Biology | Best Researcher Award

Published on by Citation Awards

Arun Jaiswal | Genetics and Molecular Biology | Best Researcher Award

Federal University of Minas Gerais, Brazil

Dr. Arun Kumar Jaiswal is a dynamic and highly motivated researcher specializing in Bioinformatics, Genomics, Proteomics, Drug Discovery, and Bacterial Diseases, with a strong focus on Treponema pallidum, the causative agent of syphilis. He earned his B.Sc. in Biotechnology, Botany, and Chemistry from Veer Kunwar Singh University, Ara, India, followed by an M.Sc. in Bioinformatics from Devi Ahilya Vishwa Vidyalaya, Indore, India. He completed his Ph.D. in Bioinformatics in 2020 at the Laboratory of Cellular and Molecular Genetics, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Brazil, where his award-winning thesis centered on pan-genomics, reverse vaccinology, and drug target identification for syphilis. Currently, he is a Residential Postdoctoral Fellow at LGCM, UFMG, supported by FAPEMIG, working on new drug target identification, pathogenomics, and vaccine development against Treponema pallidum, as well as exploring its neurological implications such as syphilitic meningitis. His expertise includes omics approaches (pan-genomics, subtractive genomics, reverse vaccinology), molecular dynamics simulations of protein–drug complexes, and next-generation sequencing data analysis. He also has growing interests in neuroinformatics and computational neuroscience to better understand neurosyphilis complications. Over the course of his career, Dr. Jaiswal has held several prestigious fellowships, including FAPEMIG and CNPq Postdoctoral Fellowships at UFMG, and an Exterior Postdoctoral Fellowship at King Abdullah University of Science and Technology, Saudi Arabia. Recognized for his academic excellence, he has received the Best Doctoral Thesis Award (2020) and a Best Poster Honorable Mention at the AB3C X-Meeting.

profile: Google Scholar | Scopus

Featured Publications

Prado, L. C. da S., Felice, A. G., Rodrigues, T. C. V., Tiwari, S., Andrade, B. S., Kato, R. B., Oliveira, C. J. F., Silva, M. V., Barh, D., Azevedo, V. A. de C., Jaiswal, A. K., & Soares, S. de C. (2021). New putative therapeutic targets against Serratia marcescens using reverse vaccinology and subtractive genomics. Journal of Biomolecular Structure and Dynamics. Taylor & Francis.

Felice, A. G., Santos, L. N. Q., Kolossowski, I., Zen, F. L., Alves, L. G., Rodrigues, T. C. V., Prado, L. C. S., Jaiswal, A. K., Tiwari, S., Miranda, F. M., Ramos, R. T. J., Azevedo, V., Oliveira, C. J. F., Benevides, L. J., & Soares, S. C. (2021). Comparative genomics of Bordetella pertussis and prediction of new vaccines and drug targets. Journal of Biomolecular Structure and Dynamics. Taylor & Francis.

Nogueira, W. G., Jaiswal, A. K., Tiwari, S., Ramos, R. T. J., Ghosh, P., Barh, D., Azevedo, V., & Soares, S. C. (2021). Computational identification of putative common genomic drug and vaccine targets in Mycoplasma genitalium. Genomics. Elsevier.

Jaiswal, A. K., Tiwari, S., Jamal, S. B., Oliveira, L. de C., Sales-Campos, H., Andrade-Silva, L. E., Oliveira, C. J. F., Ghosh, P., Barh, D., Azevedo, V., Soares, S. C., Junior, V. R., & Silva, M. V. (2021). Reverse vaccinology and subtractive genomics approaches for identifying common therapeutics against Mycobacterium leprae and Mycobacterium lepromatosis. Journal of Venomous Animals and Toxins Including Tropical Diseases.

Profeta, R., Seyffert, N., Tiwari, S., Viana, M. V. C., Jaiswal, A. K., Caetano, A. C., Bücker, D. H., Oliveira, L. T. de, Santos, R., Gala-Garcia, A., Kato, R. B., Padilh, F. F., Lima-Verde, I. B., Ghosh, P., Barh, D., Góes-Neto, A., Figueiredo, H. C. P., Soares, S. C., Meyer, R., … Castro, T. L. P. (2020). Comparative genomics with a multidrug-resistant Klebsiella pneumoniae isolate reveals the panorama of unexplored diversity in Northeast Brazil. Gene. Elsevier.

Reza Nekouian | Genetics and Molecular Biology | Pioneer Researcher Award

Published on by Citation Awards

Reza Nekouian | Genetics and Molecular Biology | Pioneer Researcher Award

Dr Reza Nekouian, Iran University of Medical Sciences, IUMS, Iran

Dr. Reza Nekouian, a seasoned faculty member at Iran University of Medical Sciences, brings over 17 years of expertise in cancer genetics and molecular diagnostics. Born on March 21, 1978, in Tehran, Iran, he has built a strong reputation in research design, academic teaching, and innovative cancer research solutions. Known for his problem-solving and leadership skills, Dr. Nekouian excels in guiding research teams and translating molecular findings into clinical applications. His academic contributions span across cancer genetics, molecular biology, and personalized medicine. In addition to being a dedicated educator in medical genetics and genetic engineering, he is also widely published in reputable journals. Dr. Nekouian is recognized for his collaborative spirit, exceptional communication, and passion for scientific innovation. His work significantly impacts early cancer detection and personalized treatments, aligning science with real-world health solutions.

Publication Profile

google scholar

Education

Dr. Reza Nekouian received his Ph.D. in Medical Biotechnology from Pune University, India, in 2007, where he specialized in cancer molecular biology and therapeutics. Prior to that, he completed his Master of Science (M.Sc.) in Health Sciences (Genetics) at the University of Pune in 2003. His academic journey reflects a focused pursuit of excellence in biotechnology and genetics, laying the foundation for his later contributions in cancer research and medical education. His studies in India exposed him to a rich scientific environment and equipped him with the latest tools in molecular genetics and biomedical research. These formative years nurtured his deep interest in translational medicine, setting him on a path to combine lab-based innovations with clinical cancer diagnostics. Dr. Nekouian’s educational background continues to fuel his research on biomarkers, cancer therapeutics, and molecular diagnostics, making him a valuable contributor to the global scientific and medical community.

Experience

Dr. Reza Nekouian has served as a faculty member and researcher at Iran University of Medical Sciences (IUMS) since February 2012. His core responsibilities include designing and managing cutting-edge research projects in cancer genetics, molecular diagnostics, and biomarker development for early cancer detection. He also actively contributes to advancing personalized medicine approaches in oncology. As a dedicated educator, Dr. Nekouian teaches theoretical and practical courses in medical genetics and genetic engineering, inspiring the next generation of scientists and clinicians. His professional journey spans over 17 years of impactful work at medical universities and research centers. He is recognized for his skill in resolving complex genetic and molecular research challenges, leading multidisciplinary teams, and publishing groundbreaking findings. With a focus on translational research, he bridges laboratory innovations with patient-centric medical applications, thereby improving diagnostic precision and therapeutic strategies in cancer treatment.

Awards and Honors

Although specific awards are not listed in the profile, Dr. Reza Nekouian’s extensive contributions to cancer genetics, personalized medicine, and molecular diagnostics have earned him academic distinction and professional recognition across Iranian and international research communities. His consistent publication in reputed journals, leadership in high-impact research, and role in educational development underscore his influence in the field. Dr. Nekouian has been instrumental in pioneering research programs and contributing to national strategies for cancer prevention and diagnosis. His invited roles in collaborative projects, advisory panels, and journal editorial activities serve as implicit recognition of his expertise. He is regularly consulted for complex research problem-solving and project development, particularly in molecular biology and biotechnology. Additionally, his leadership in implementing cancer control initiatives in the private health sector highlights his commitment to both scientific excellence and societal health advancement.

Research Focus

Dr. Reza Nekouian’s research centers on cancer genetics, with a specialized focus on the molecular mechanisms of tumorigenesis and biomarker discovery for early detection. His work explores the genetic regulation of cancer progression, using advanced diagnostic tools like circulating microRNAs and liposomal drug delivery systems. He also investigates personalized medicine approaches, including the role of gene expression and polymorphisms in cancer susceptibility and therapeutic response. A recurring theme in his research is the integration of molecular diagnostics with clinical oncology, aiming to improve diagnostic accuracy and treatment precision. Dr. Nekouian has contributed significantly to breast, gastric, and colorectal cancer research, evaluating biomarkers like miRNAs, HLA-G, and FOXP3, and exploring innovative cancer therapies using viral vectors and nanotechnology. His interdisciplinary approach blends molecular biology, bioinformatics, and pharmacogenomics to enhance patient outcomes and reduce cancer mortality through early, personalized interventions.

Publication Top Notes

📄 Evaluation of the in vitro and in vivo effect of liposomal doxorubicin with Newcastle disease virus on 4T1 cell line (2023)
📄 Plasma miR-183-5p as a predictive lymph node metastasis marker in colorectal cancer (2022)
📄 Effect of testosterone enanthate on liver Irs-2 mRNA expression in PCOS model rats (2021)
📄 Meta-analysis of serum HLA-G level accuracy in breast cancer diagnosis (2020)
📄 Expression of angiogenesis-related genes in Iranian breast cancer patients (2020)
📄 Epidemiological study of postsurgical invasive breast cancer cases in Iran (2020)
📄 Use of software in detecting angiogenesis in breast tissue slides (2020)
📄 Meta-analysis of FOXP3 polymorphisms and multiple sclerosis susceptibility (2020)
📄 Evaluation of miR-21 and miR-222 as diagnostic biomarkers for gastric cancer (2019)
📄 Nanocomposite scaffold with MSCs for bone repair applications (2019)
📄 Study on protein-binding malondialdehyde in breast cancer tissues (2019)
📄 Management of biotechnology industry in the West and solutions for Iran (2018)
📄 In vitro effects of Lactobacillus reuteri on gastric cancer progression (2017)
📄 Implementation of private sector cancer prevention programs in Iran (2017)
📄 Study on BRCA1/2 mutations in women with breast cancer family history (2016)
📄 Anti-fibronectin gold nanoparticle biosensor for ECM detection (2014)
📄 Iranian consumers’ shift to functional foods for healthier lifestyle (2014)
📄 FOXP3 mRNA downregulation by Alkanna Frigida extract (2013)
📄 H-semigroup structure on F-offspring of a gene pool (2012)

Anna Lankoff | Genetics and Molecular Biology | Best Researcher Award

Published on by Citation Awards

Anna Lankoff | Genetics and Molecular Biology | Best Researcher Award

Prof Anna Lankoff, Institute of Nuclear Chemistry and Technology, Centre for Radiobiology and Biological Dosimetry, Poland

Prof. Anna Lankoff is a distinguished scientist and educator renowned for her contributions to genotoxicology, nanotoxicology, and radiobiology. 👩‍🔬🧪 With over three decades of experience, she has made groundbreaking advancements in the study of ionizing radiation-induced DNA damage, nanoparticle-based radioconjugates for cancer therapy, and cellular responses to nanomaterials. 🌐🔬 Currently, she holds full professorships at both the Institute of Nuclear Chemistry and Technology in Warsaw and Jan Kochanowski University in Kielce, where she leads the Cytogenetics and Genotoxicology Laboratories. 💡📘 Her collaborative work spans across institutions in Germany, Finland, Belgium, and the USA. She is a respected academic leader, actively participating in global expert committees including WHO-IARC and the European Radiation Research Council. 🌍📚 With 85 peer-reviewed papers, 3797 citations, and an h-index of 30, Prof. Lankoff exemplifies excellence in research and education, making her an ideal candidate for the Best Researcher Award. 🏆🔝

Publication Profile

Orcid

Education 

Prof. Anna Lankoff began her academic journey with an MSc in Biology (1986–1991) from Jan Kochanowski University, Kielce, Poland. 🎓🔬 She earned her PhD in Toxicology in 1999 from Maria Sklodowska-Curie University in Lublin, Poland. 💊📘 Her research prowess led her to complete a prestigious postdoctoral fellowship in 2003 at Wright State University in Dayton, Ohio, USA, in the Department of Biological Sciences. 🌍🧬 In 2007, she achieved her DSc (habilitation) in Biological Sciences from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. 🧫📖 By 2014, she was awarded the title of Full Professor in Biological Sciences, marking a significant milestone in her academic career. 🌟 Her extensive academic preparation laid the foundation for a prolific scientific and educational path in radiobiology, cytogenetics, and nanotoxicology. 🧠💼

Experience 

Prof. Lankoff has an extensive academic and research career. Since 2014, she has been a Full Professor at both the Institute of Nuclear Chemistry and Technology, Warsaw, and Jan Kochanowski University, Kielce. 🧪🇵🇱 She leads laboratories in cytogenetics and genotoxicology. From 2009–2014, she served as Associate Professor at these institutions, and previously, as a lecturer and assistant since 1991. 📘👩‍🏫 Her international experience includes research stints at University of Duisburg-Essen (Germany), Wright State University (USA), VITO (Belgium), and Åbo Akademi University (Finland). 🌐🔍 She has mentored numerous students and professionals in molecular biology, immunology, and nanotoxicology. Her professional journey reflects dedication to excellence in both teaching and cutting-edge scientific research. 💡🧬

Awards and Honors 

Prof. Anna Lankoff’s contributions have been recognized internationally. 🌟 She was a working group member for the WHO-IARC (2006) and an expert for the EU’s “Epigenetic effects” radiation protection group (2017). 🌍🔬 She represented Poland on the ISO Radiology Standards Committee (2010–2015) and serves on the Scientific Council of the Institute of Nuclear Chemistry and Technology and the Polish Society for Radiation Research. 🇵🇱📘 She is also a member of the European Radiation Research Council since 2022. 🧪💡 Her work has earned her recognition for developing standards in biological dosimetry and contributions to nanotoxicology and radiation biology. 📜🔝 With a prolific academic record of 85 JCR-listed publications and over 3,700 citations, she holds an h-index of 30. 📚 Her impactful global collaborations, editorial work, and advisory roles highlight her as a true leader in radiobiological research and innovation. 🧬🏆

Research Focus 

Prof. Lankoff’s research integrates nanotechnology, radiobiology, and molecular biology. 🧬 Her focus areas include the genotoxicity and cytotoxicity of nanomaterials, development of nanoparticle-based radioconjugates for targeted cancer diagnosis and therapy, and the mechanisms of DNA damage and repair induced by ionizing radiation. 💥🧪 She investigates cellular responses such as cell cycle arrest, apoptosis, and pyroptosis in reaction to nanomaterial exposure and radiation treatment. 🧫 Her recent work explores nanotheranostics, blackcurrant-derived antioxidants, and radiosensitization strategies using natural compounds. 🌿💉 She also delves into biodistribution, pharmacokinetics of engineered nanostructures, and radiobiological safety, bridging basic science with translational medicine. 🌐🧠 Prof. Lankoff’s innovative research contributes to the development of safer nanomaterials and more effective cancer therapies, reinforcing her status as a pioneering researcher in modern molecular and radiation biology. 🧪🔬📈

Publication Top Notes

  1. 📘 Advances in Nanotheranostic Systems for Concurrent Cancer Imaging and Therapy: An Overview of the Last 5 Years (2024)

  2. 🧪 Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer (2023)

  3. ☢️ Hypothermia Modulates NBS1, γH2AX and 53BP1 Foci in U2OS Cells Post Gamma Radiation (2022)

  4. 🍇 Blackcurrant Pomace Protects Rats from Testicular Oxidative Stress from Biodiesel Exhaust (2022)

  5. 🔬 Surface Modification of Gold Nanoparticles Triggers Pyroptosis-Inducing Cytokine Release (2022)

  6. 💉 Targeted NaA Nanozeolites for Prostate Cancer Therapy: Toxicity and Pharmacokinetics (2021)

  7. 🧬 Cisplatin Lowers Radiotherapy-Induced Micronuclei in Lymphocytes of Gynaecological Cancer Patients (2021)

  8. 📈 Coralyne Radiosensitizes A549 Cells by CDKN1A Upregulation Affecting G2/M Cell Cycle Arrest (2021)

 

Santina Bruzzone | Genetics and Molecular Biology | Best Researchers Award

Published on by Citation Awards

Santina Bruzzone | Genetics and Molecular Biology | Best Researchers Award

Santina Bruzzone,Università di Genova,Italy

Santina Bruzzone is a Full Professor of Biochemistry at the University of Genova, Italy. She was born on February 21, 1972, in Genova, Italy. Her research focuses on the role of NAD+ and NAD+-converting enzymes in inflammation and cancer.

Publication Profile

Scopus

Education

Santina Bruzzone completed her high school education at Liceo Scientifico L. Lanfranconi in Genova, Italy, from 1986 to 1991. She then earned her degree in Biology from the University of Genova, graduating cum laude with a score of 110/110 in 1996. She received her Ph.D. in Biotechnology applied to Pharmacology and Cellular and Molecular Biotechnology applied to Biomedicine from the University of Milano from 1996 to 2000.

Experince

Santina Bruzzone worked as a postdoctoral researcher at the Department of Experimental Medicine (DIMES)–Section of Biochemistry, University of Genova, from January to March 2001. She then worked as a postdoctoral researcher at the Department of Pharmacology, University of Minnesota, from April to December 2001. She returned to the University of Genova as a postdoctoral researcher from 2002 to 2005 and later became an Assistant Professor of Biochemistry from 2005 to 2016. She was promoted to Associate Professor of Biochemistry from 2016 to 2021 and became a Full Professor of Biochemistry in 2021.

Award and Honors

Santina Bruzzone received several awards and honors, including the Fellowship for training abroad from Consorzio Interuniversitario Biotecnologie (CIB) in 2001, the Fellowship for training abroad from the University of Genova in 2001, and the Faculty Research Visit Grant from DAAD (German Academic Exchange Service) in 2013.

Research Focus

Santina Bruzzone’s research focuses on the role of NAD+ and NAD+-converting enzymes in inflammation and cancer. Her work explores the molecular mechanisms underlying the regulation of NAD+ metabolism and its impact on cellular processes such as energy metabolism, cell signaling, and cell death.

Publications

1. 🌟 CD38 and ADP-ribosyl cyclase catalyze the synthesis of a dimeric ADP-ribose that potentiates the Calcium-mobilizing activity of Cyclic ADP-ribose. (1997)
2. 🌟 Ectocellular CD38-catalyzed synthesis and intracellular Ca2+-mobilizing activity of Cyclic ADP-ribose. (1998)
3. 🌟 Expression of CD38 increases intracellular calcium concentration and reduces doubling time in HeLa and 3T3 cells. (1998)
4. 🌟 The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger Cyclic ADPribose across membranes. (1998)
5. 🌟 Dimeric and tetrameric forms of catalytically active transmembrane CD38 in transfected HeLa cells. (1998)
6. 🌟 Ligand-induced internalization of CD38 results in intracellular Ca2+ mobilization. (1999)
7. 🌟 Topology of CD38. (2000)
8. 🌟 Extracellular cyclic ADP-ribose increases intracellular free calcium concentration and stimulates proliferation of human hemopoietic progenitors. (2000)
9. 🌟 G(s) protein dysfunction in allergen-challenged human isolated passively sensitized bronchi. (2000)
10. 🌟 Connexin 43 hemichannels mediate Ca2+-regulated transmembrane NAD+ fluxes in intact cells. (2001)
11. 🌟 Extracellular Cyclic ADP-ribose potentiates Ach-induced contraction in bovine tracheal smooth muscle. (2001)
12. 🌟 Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway. (2001)
13. 🌟 Paracrinally stimulated expansion of early human hemopoietic progenitors by stroma-generated cyclic ADP-ribose. (2001)
14. 🌟 Paracrine roles of NAD+ and Cyclic ADP-ribose in increasing intracellular calcium and enhancing cell proliferation of 3T3 fibroblasts. (2001)
15. 🌟 Autocrine abscisic acid mediates the UV-B-induced inflammatory response in human granulocytes and keratinocytes. (2012)
16. 🌟 ABA says NO to UV-B: a universal